- Home
- EXAS vs VRNA Comparison
EXAS vs VRNA Comparison
Compare EXAS & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- VRNA
- Stock Information
- Founded
- EXAS 1995
- VRNA 2005
- Country
- EXAS United States
- VRNA United Kingdom
- Employees
- EXAS N/A
- VRNA N/A
- Industry
- EXAS Medical Specialities
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- EXAS Health Care
- VRNA Health Care
- Exchange
- EXAS Nasdaq
- VRNA Nasdaq
- Market Cap
- EXAS 10.7B
- VRNA N/A
- IPO Year
- EXAS N/A
- VRNA 2017
- Fundamental
- Price
- EXAS $56.28
- VRNA $81.20
- Analyst Decision
- EXAS Strong Buy
- VRNA Strong Buy
- Analyst Count
- EXAS 20
- VRNA 5
- Target Price
- EXAS $70.68
- VRNA $77.80
- AVG Volume (30 Days)
- EXAS 3.6M
- VRNA 1.3M
- Earning Date
- EXAS 07-30-2025
- VRNA 04-29-2025
- Dividend Yield
- EXAS N/A
- VRNA N/A
- EPS Growth
- EXAS N/A
- VRNA N/A
- EPS
- EXAS N/A
- VRNA N/A
- Revenue
- EXAS $2,828,128,000.00
- VRNA $118,535,000.00
- Revenue This Year
- EXAS $14.58
- VRNA $890.44
- Revenue Next Year
- EXAS $12.75
- VRNA $77.74
- P/E Ratio
- EXAS N/A
- VRNA N/A
- Revenue Growth
- EXAS 11.57
- VRNA N/A
- 52 Week Low
- EXAS $39.97
- VRNA $11.39
- 52 Week High
- EXAS $72.83
- VRNA $81.73
- Technical
- Relative Strength Index (RSI)
- EXAS 61.48
- VRNA 70.84
- Support Level
- EXAS $55.26
- VRNA $73.14
- Resistance Level
- EXAS $58.68
- VRNA $76.92
- Average True Range (ATR)
- EXAS 1.98
- VRNA 3.43
- MACD
- EXAS -0.14
- VRNA 0.66
- Stochastic Oscillator
- EXAS 64.86
- VRNA 97.50
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.